A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors

PURPOSE: Ridaforolimus (AP23573, MK-8669 or deforolimus) is an inhibitor of mammalian target of rapamycin (mTOR), an important regulator in the cell survival pathway. This open-label, single center phase I study aimed to investigate the pharmacokinetic (PK) and safety profiles of ridaforolimus in Ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lian, Zhang, Wen, Li, Wenhua, Lv, Fangfang, Xia, Zuguang, Zhang, Sheng, Liu, Wen, Zandvliet, Anthe S, Waajen, Sylvia, Zhang, Li Xin, Yan, Li, Li, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716995/
https://www.ncbi.nlm.nih.gov/pubmed/23829943
http://dx.doi.org/10.1186/1756-8722-6-48

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716995/
https://www.ncbi.nlm.nih.gov/pubmed/23829943
http://dx.doi.org/10.1186/1756-8722-6-48

Ejemplares similares